Aytu BioPharma (AYTU) Expected to Announce Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) is projected to issue its Q2 2026 results before the market opens on Wednesday, February 11th. Analysts expect Aytu BioPharma to post earnings of ($0.26) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, February 3, 2026 at 4:30 PM ET.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.79). The business had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million. Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%.

Aytu BioPharma Stock Up 3.9%

NASDAQ:AYTU opened at $2.39 on Monday. The firm has a market capitalization of $25.64 million, a P/E ratio of -0.62 and a beta of 0.37. Aytu BioPharma has a 1-year low of $0.95 and a 1-year high of $3.07. The company’s fifty day moving average price is $2.52 and its 200-day moving average price is $2.34. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.16 and a quick ratio of 1.03.

Analyst Ratings Changes

Several equities research analysts have commented on AYTU shares. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th. Ascendiant Capital Markets raised their target price on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aytu BioPharma has an average rating of “Hold” and an average target price of $9.33.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently bought a new stake in Aytu BioPharma stock. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma Inc. (NASDAQ:AYTU) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 30,964 shares of the company’s stock, valued at approximately $58,000. Dimensional Fund Advisors LP owned approximately 0.30% of Aytu BioPharma as of its most recent SEC filing. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.